Organisation paid for research Program year 2024 Source: CMS Open Payments

Bluegrass Community Research

Neither a doctor nor a teaching hospital

Research payments

$793,861

66 payments

Through program year 2024, Bluegrass Community Research is reported as receiving $793,861 in research payments, across 66 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $15,676 1
2023 Research $169,885 5
2022 Research $200,733 4
2021 Research $177,212 20
2020 Research $155,170 9
2019 Research $75,185 27

Breakdown

Who paid Research payments · program years 2019–2024
  1. Ucb SA $491,883 33 payments
  2. Horizon Therapeutics plc $219,209 4 payments
  3. Novartis Pharmaceuticals Corporation $31,888 2 payments
  4. UCB, Inc. $24,494 1 payment
  5. Amgen Inc. $16,476 3 payments
  6. Dr.Reddy's Laboratories,Inc. $7,000 3 payments
  7. Hexal AG $2,910 20 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $226,116 12 payments
  2. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Vib7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus $178,310 2 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Pso $82,178 2 payments
  4. A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $78,386 6 payments
  5. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $72,194 5 payments
  6. An Open-Label Extension Study to Evaluate the Long- Term Safety and Tolerability of Daxdilimab (Hzn-7734) in Subjects With Systemic Lupus Erythematosus $40,899 2 payments
  7. A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) $31,888 2 payments
  8. A Multicenter, Open-Label Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis $24,494 1 payment
  9. A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $16,764 2 payments
  10. A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluatethe Efficacy and Safety of Bimekizumab in Activepsoriatic Arthritis $8,823 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record